299 related articles for article (PubMed ID: 23406896)
1. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.
Shah DK; Betts AM
MAbs; 2013; 5(2):297-305. PubMed ID: 23406896
[TBL] [Abstract][Full Text] [Related]
2. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
3. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
[TBL] [Abstract][Full Text] [Related]
4. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
5. Prediction of tissue concentrations of monoclonal antibodies in mice from plasma concentrations.
Mahmood I; Tegenge MA
Regul Toxicol Pharmacol; 2018 Aug; 97():57-62. PubMed ID: 29894734
[TBL] [Abstract][Full Text] [Related]
6. A translational platform PBPK model for antibody disposition in the brain.
Chang HY; Wu S; Meno-Tetang G; Shah DK
J Pharmacokinet Pharmacodyn; 2019 Aug; 46(4):319-338. PubMed ID: 31115858
[TBL] [Abstract][Full Text] [Related]
7. Whole-Body Disposition and Physiologically Based Pharmacokinetic Modeling of Adeno-Associated Viruses and the Transgene Product.
Liu S; Chowdhury EA; Xu V; Jerez A; Mahmood L; Ly BQ; Le HK; Nguyen A; Rajwade A; Meno-Tetang G; Shah DK
J Pharm Sci; 2024 Jan; 113(1):141-157. PubMed ID: 37805073
[TBL] [Abstract][Full Text] [Related]
8. Application of PBPK modeling to predict monoclonal antibody disposition in plasma and tissues in mouse models of human colorectal cancer.
Abuqayyas L; Balthasar JP
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):683-710. PubMed ID: 23184417
[TBL] [Abstract][Full Text] [Related]
9. Clinical validation of translational antibody PBPK model using tissue distribution data generated with
Liu S; Li Z; Huisman M; Shah DK
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):377-394. PubMed ID: 37382712
[TBL] [Abstract][Full Text] [Related]
10. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Balthasar JP; Jusko WJ
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
[TBL] [Abstract][Full Text] [Related]
11. Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice.
Li Z; Li Y; Chang HP; Yu X; Shah DK
J Pharmacokinet Pharmacodyn; 2021 Oct; 48(5):743-762. PubMed ID: 34146191
[TBL] [Abstract][Full Text] [Related]
12. Survey of monoclonal antibody disposition in man utilizing a minimal physiologically-based pharmacokinetic model.
Cao Y; Jusko WJ
J Pharmacokinet Pharmacodyn; 2014 Dec; 41(6):571-80. PubMed ID: 25146360
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of near infrared fluorescent labeling of monoclonal antibodies as a tool for tissue distribution.
Conner KP; Rock BM; Kwon GK; Balthasar JP; Abuqayyas L; Wienkers LC; Rock DA
Drug Metab Dispos; 2014 Nov; 42(11):1906-13. PubMed ID: 25209366
[TBL] [Abstract][Full Text] [Related]
14. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.
Wang-Lin SX; Zhou C; Kamath AV; Hong K; Koppada N; Saad OM; Carrasco-Triguero M; Khojasteh C; Deng R
MAbs; 2018 Oct; 10(7):1131-1143. PubMed ID: 30081725
[TBL] [Abstract][Full Text] [Related]
15. Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis.
Jadhav SB; Khaowroongrueng V; Fueth M; Otteneder MB; Richter W; Derendorf H
J Pharm Sci; 2017 Sep; 106(9):2853-2859. PubMed ID: 28414146
[TBL] [Abstract][Full Text] [Related]
16. Preclinical characterization of the ADME properties of a surrogate anti-IL-36R monoclonal antibody antagonist in mouse serum and tissues.
Conner KP; Pastuskovas CV; Soto M; Thomas VA; Wagner M; Rock DA
MAbs; 2020; 12(1):1746520. PubMed ID: 32310023
[TBL] [Abstract][Full Text] [Related]
17. Predicting monoclonal antibody pharmacokinetics following subcutaneous administration via whole-body physiologically-based modeling.
Hu S; D'Argenio DZ
J Pharmacokinet Pharmacodyn; 2020 Oct; 47(5):385-409. PubMed ID: 32500362
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and dosimetry following infusion of antibodies labeled with large amounts of 131I.
Badger CC; Davis J; Nourigat C; Wu ZM; Hui TE; Fisher DR; Shulman H; Appelbaum FR; Eary JF; Krohn KA
Cancer Res; 1991 Nov; 51(21):5921-8. PubMed ID: 1682038
[TBL] [Abstract][Full Text] [Related]
19. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
20. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
